Onco Actu du 6 octobre 2017

	1. Biologie
2017 Nobel Prize in Chemistry: how making microscopes cool is helping cancer research [Cancer Research UK] “Cryo-EM is exciting because it allows us to study the structure of biological molecules that we previously weren’t able to, in incredible detail,” says Professor Richard Bayliss, a Cancer Research UK-funded structural biology expert from the University of Leeds.
	2. Etiologie
Study Identifies Crucial Characteristic of High-Risk HPV [NCI] “We knew that E7 was important, but we didn’t realize that its genetic conservation might be critical for HPV16 to cause cancer,” said lead investigator Lisa Mirabello.
	2.6 Etiologie - Environnement
EU set to delay vote on weed-killer glyphosate [Reuters] France, which is opposed to a 10-year extension, has put forward the idea of a shorter extension for glyphosate with a view to phasing it out.
	4.1 Dép., diag. & prono. - Prostate
Strata Oncology, UCSF Partner to Offer $25M in Free Tumor Sequencing [Xconomy] Called StratifyProstate, the initiative aims to dramatically increase enrollment in relevant precision medicine trials, says Strata CEO Dan Rhodes.
	5.1 Traitements - Pré-clinique
A new CRISPR-engineered cancer model to test therapeutics [Broad Institute] New technique for modeling human leukemia in mice may aid drug discovery, clinical trials.
	5.12.2 Immunothérapies - CAR-T
As CAR-T launch ramps up in U.S., Novartis' Narasimhan looks to convince Japan on performance-based pricing [FiercePharma] Novartis plans to apply for Kymriah coverage under Japan's national insurance next year, according to Nikkei. That review should take seven to nine months, the publication reports, with a price determination coming two months after.
	5.12.8 Immunothérapies - Economie
Roche bladder cancer drug struggles as medics focus on survival [Reuters] Merck’s drug has seen its market share in bladder cancer rise to 16 percent since the Roche setback.
	5.2.3 Pharma - économie
Eli Lilly defeats challenge to Alimta cancer drug patent [Reuters] Alimta is Lilly’s third biggest-selling drug, accounting for $2.28 billion of the Indianapolis-based company’s $21.22 billion of revenue last year, a regulatory filing shows. Lilly has said it begins losing patent protection in 2021.
	5.3 Traitements - FDA, EMA, NICE...
Most cancer drugs approved by EMA show little benefit: study [PharmaTimes] Out of all the indications, only 35 (51%) had shown a significant improvement in survival or quality of life, while 33 (49%) remained uncertain.
Half the cancer drugs approved in Europe recently don’t significantly help patients [STAT] The European Medicines Agency declined to comment on the research.
Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study [Cancer Research UK] Emma Greenwood, Cancer Research UK’s director of policy, said the findings were useful, but might not reflect the drugs that are available in the UK as it has another layer of approval for drugs, and that the system has changed since the period under study.
Faster, pricier and often worthless: Study slams regulators for wave of questionable cancer drug OKs [EndPoints] The two authors — Courtney Davis at King’s College in London, and Huseyin Naci of LSE Health — say 39 indications (57%) were sanctioned “without evidence of a survival or quality of life benefit.” And they excoriated the use of surrogate endpoints, saying they are unreliable at best.
	5.3.4 Traitements - AMM (FDA, EMA)
Lilly Receives U.S. FDA Approval of Verzenio™ (abemaciclib) [Lilly] Verzenio is the only CDK4 & 6 inhibitor approved with a continuous dosing schedule.
	6.1 Observation
Global burden of disease study focuses on liver cancer [ecancernews] Cases of incident (new) liver cancer increased 75 percent between 1990 and 2015, which was mostly explained by population aging and population growth, according to the authors.
	6.11 Patients
Cancer patients need more than survival [The Guardian] That is why, whatever drugs come down the pipeline in the next few years, quality of life should underpin any and all medical research. For what is the point of simply surviving – not living – if your existence is a painful, feeble and miserable one?
The Scary Future of Cancer Therapy [HuffPost] Nurses and social workers were mobilized, equipment was delivered to her home, and her family gathered to be with her. But then, the very next day, the FDA approved a drug that treats the exact subtype of AML that she has, one that doesn't work more often than it does, and one that has not been shown to improve a person’s survival.
	6.5 Médecines alternatives
Complementary and Alternative Medicines and Cancer [Science-Based Medicine] Surveys suggest that CAM use by cancer patients is fairly common. Whether you’re currently being treated for cancer or are a health professional who treats cancer patients, it’s important to understand the types of CAM, the impact of CAM on cancer, and how to make informed decisions about using CAM.
	6.6 Publications
Early data on potential anti-cancer compound now in human trials was falsified, company admits [Retraction Watch] The data, published as an abstract in August 2015 in the journal Cancer Research, reported a therapeutic benefit of acalabrutinib in a mouse model of pancreatic cancer.